Press & News

The next generation biopharmaceuticals

Press releases 2013

2013-11-19

Interim Report – January to September 2013

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the Third Quarter 2013.[read more]

Older press releases

2013-11-05

Sobi announces phase I Complement Inhibitor program

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial today at the company’s Capital Markets Event in Stockholm.[read more]

2013-10-01

EU Funded Effort to Develop New Stroke Therapies

Solna, Sweden, October 1, 2013. The COUNTERSTROKE consortium led by researchers at Karolinska Institutet today initiates a six million Euro EU funded collaboration to develop novel therapeutics to treat stroke.[read more]

2013-09-17

New molecular imaging agents being developed for fluorescence-guided brain cancer surgery

Solna, Sweden, September 17, 2013. Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery.[read more]

Affibodys latest Press releases

2021-06-02

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby given notice...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information